We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Inflarx NV (IFRX) NPV

Sell:$2.61 Buy:$2.63 Change: $0.13 (4.98%)
NASDAQ:0.05%
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$2.61
Buy:$2.63
Change: $0.13 (4.98%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$2.61
Buy:$2.63
Change: $0.13 (4.98%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

Contact details

Address:
Winzerlaer Str. 2
JENA
07745
Germany
Telephone:
+49 (3641) 508180
Website:
https://www.inflarx.de/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IFRX
ISIN:
NL0012661870
Market cap:
$147.68 million
Shares in issue:
58.88 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Netherlands
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Niels Riedemann
    Chief Executive Officer, Executive Director
  • Thomas Taapken
    Chief Financial Officer
  • Derval O'Carroll
    Senior Vice President, Global Head of Regulatory Affairs and Compliance
  • Renfeng Guo
    Chief Scientific Officer, Executive Director
  • Camilla Chong
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.